{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:46:18Z","timestamp":1790718378130,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,9]]},"DOI":"10.7759\/cureus.48555","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T11:59:11Z","timestamp":1699531151000},"source":"Crossref","is-referenced-by-count":3,"title":["Dasatinib-Triggered Severe Hypocalcemia in a Patient with Chronic Kidney Disease and Osteoporosis"],"prefix":"10.7759","author":[{"given":"Kohei","family":"Shiroshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sadahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes J","year":"2021","unstructured":"Cortes J, Pavlovsky C, Sau\u00dfele S. Chronic myeloid leukaemia. Lancet. 2021, 398:1914-1926. 10.1016\/s0140-6736(21)01204-6","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system","volume":"109","author":"Kizaki M","year":"2019","unstructured":"Kizaki M, Takahashi N, Iriyama N, et al.. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019, 109:426-39. 10.1007\/s12185-019-02613-1","journal-title":"Int J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid IR","year":"2022","unstructured":"Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022, 399:1080-1092. 10.1016\/s0140-6736(21)02646-5","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem A","year":"2023","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al.. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023, 176:224-38. 10.7326\/M22-1034","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai K","year":"2021","unstructured":"Murai K, Ureshino H, Kumagai T, et al.. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021, 8:902-911. 10.1016\/s2352-3026(21)00333-1","journal-title":"Lancet Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian HM","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, et al.. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012, 119:1123-9. 10.1182\/blood-2011-08-376087","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, et al.. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017, 376:917-27. 10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al.. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016, 34:2333-40. 10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus A","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, et al.. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016, 30:1044-54. 10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim TD","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, et al.. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013, 27:1316-21. 10.1038\/leu.2013.70","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman E","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG, et al.. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006, 354:2006-13. 10.1056\/NEJMoa051140","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40368","article-title":"Osteoporosis in a 60-year-old male with a history of chronic myeloid leukemia treated with imatinib mesylate","volume":"15","author":"Batra J","year":"2023","unstructured":"Batra J, Ankireddypalli AR, Kanugula AK, Gorle S, Kaur J. Osteoporosis in a 60-year-old male with a history of chronic myeloid leukemia treated with imatinib mesylate. Cureus. 2023, 15:e40368. 10.7759\/cureus.40368","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan S","year":"2007","unstructured":"O'Sullivan S, Naot D, Callon K, et al.. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res. 2007, 22:1679-89. 10.1359\/jbmr.070719","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.04.014","article-title":"The skeletal effects of the tyrosine kinase inhibitor nilotinib","volume":"49","author":"O'Sullivan S","year":"2011","unstructured":"O'Sullivan S, Lin JM, Watson M, et al.. The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone. 2011, 49:281-9. 10.1016\/j.bone.2011.04.014","journal-title":"Bone"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-298","article-title":"The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts","volume":"10","author":"Id Boufker H","year":"2010","unstructured":"Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ, Journ\u00e9 F. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer. 2010, 10:298. 10.1186\/1471-2407-10-298","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.151.2.311","article-title":"Decreased c-Src expression enhances osteoblast differentiation and bone formation","volume":"151","author":"Marzia M","year":"2000","unstructured":"Marzia M, Sims NA, Voit S, et al.. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000, 151:311-20. 10.1083\/jcb.151.2.311","journal-title":"J Cell Biol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.356","article-title":"Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis","volume":"23","author":"Vandyke K","year":"2009","unstructured":"Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, Hughes TP, Zannettino AC. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia. 2009, 23:994-7. 10.1038\/leu.2008.356","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034914","article-title":"Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects","volume":"7","author":"Garcia-Gomez A","year":"2012","unstructured":"Garcia-Gomez A, Ocio EM, Crusoe E, et al.. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One. 2012, 7:e34914. 10.1371\/journal.pone.0034914","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.0550031019.x","article-title":"Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure","volume":"55","author":"Ishimura E","year":"1999","unstructured":"Ishimura E, Nishizawa Y, Inaba M, et al.. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999, 55:1019-27. 10.1046\/j.1523-1755.1999.0550031019.x","journal-title":"Kidney Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block GA","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012, 27:1471-9. 10.1002\/jbmr.1613","journal-title":"J Bone Miner Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/203741-dasatinib-triggered-severe-hypocalcemia-in-a-patient-with-chronic-kidney-disease-and-osteoporosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:46Z","timestamp":1707509446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/203741-dasatinib-triggered-severe-hypocalcemia-in-a-patient-with-chronic-kidney-disease-and-osteoporosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.48555","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}